We recently published a list of 10 Top Insider Stock Buys And Sells In January. In this article, we are going to take a look at where Ionis Pharmaceuticals (NASDAQ:IONS) stands against other top ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...

IONIS PHARMACEUTICALS ($IONS) posted quarterly earnings results on Wednesday, February 19th. The company reported earnings of -$0.66 per share, beating estimates of ...

William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...

Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the ...

Positive Phase 3 results for TRYNGOLZA in sHTG could drive significant revenue growth, potentially doubling the stock's market cap to $10B. Investors should be aware of this potential, as IONS ...

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an ...